Genomic Risk Markers for Atrial Fibrillation Following Cardiac Rhythm Monitoring
Atrial fibrillation (AFib) is the most commonly encountered heart arrhythmia. About 20% of strokes are known to be caused by documented AFib. However, because AFib is often undocumented and difficult to detect, it is thought that the true proportion of strokes due to this type of heart arrhythmia may be much higher.
More effective screening strategies of AFib, a treatable condition, have the potential to significantly reduce the morbidity associated with stroke. The Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Monitoring (GIRAFFE) study is designed to determine whether genetic risk scores for AFib can identify individuals at high risk of undiagnosed AFib.
During study enrollment, patients presenting to their outpatient doctor with symptoms leading to high clinical suspicion of AFib and at least one clinical risk factor of AFib were recruited to have genetic testing and to wear an ambulatory cardiac rhythm monitor called ZIO Patch for two weeks.
Over 900 participants successfully completed the study.